THAR vs TLRY · $187.4M cap vs rev $821.3M
Tharimmune Inc. (THAR) versus Tilray Inc (TLRY) — a side-by-side from cached financials, not a winner call.
Tharimmune Inc. (THAR) is a biotechnology company listed on NASDAQ.
Tilray Inc (TLRY) is a drug manufacturers - specialty & generic company listed on NASDAQ.
THAR does not have a complete income-statement cache yet.
Latest reported TLRY revenue for 2025-05-31 was $821.3M. Net income was -$2.18B. Revenue was up 4.1% from 2024-05-31 to 2025-05-31. TLRY currently screens at market cap $573.9M.
THAR currently screens at market cap $187.4M. TLRY currently screens at market cap $573.9M.
Not investment advice. Open the THAR and TLRY stock pages for the full models.
Not investment advice.